Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Dolutegravir/Rilpivirine FDC; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Long Beach, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 4 more

Conditions: HIV Infections
Interventions: DTG 50 mg, RPV 25 mg, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 13
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more

Conditions: HIV-1-infection, HIV Infections, HIV I Infection
Interventions: CAB + RPV; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV-1-Infection
Interventions: ISL/LEN, Antiretroviral Combinations; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more

Conditions: HIV-1
Interventions: Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Syracuse, New York • Memphis, Tennessee

Conditions: HIV-1-infection
Interventions: Once daily CAB tablet + RPV tablet, Long acting CAB injectable + long acting RPV injectable; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 11 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Atlanta, Georgia • Memphis, Tennessee

Conditions: HIV Infection
Interventions: Highly active antiretroviral therapy (HAART); Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 26
States / cities: Alhambra, California • Los Angeles, California • San Diego, California + 20 more

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: Long Beach, California • Los Angeles, California • San Diego, California + 12 more

Conditions: HIV Infections
Interventions: Raltegravir (RAL), Atazanavir (ATV), Ritonavir (RTV), Tenofovir (TDF), Etravirine (ETV), Darunavir (DRV), Maraviroc (MVC), Lopinavir/ritonavir (LPV/r); Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 6 Years to 21 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 33
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 21 more

Conditions: HIV Infections
Interventions: Cabotegravir 200 mg/mL, Cabotegravir >=400 mg/mL, Cabotegravir Formulation I, CAB Formulation J, rHuPH20, RPV; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Orlando, Florida • Las Vegas, Nevada • Austin, Texas

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: DTG, RPV, DTG/RPV FDC; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV-1-infection
Interventions: B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Bakersfield, California • Palm Springs, California • San Diego, California + 7 more

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TDF, EFV/FTC/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 59 more

Conditions: HIV Treatment, HIV Prevention
Interventions: At Home Self-Collections; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: RPV LA, CAB LA; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: HIV-1-infection, Pregnancy, Postpartum
Interventions: CAB LA 600mg, RPV LA 900mg, CAB LA 400mg, RPV LA 600mg; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Baltimore, Maryland + 1 more

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions: Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Macon, Georgia • Austin, Texas • Bellaire, Texas + 2 more

Conditions: HIV Infections
Interventions: Subjects do not receive study medication in this study 202094; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: HIV -1 Infection
Interventions: Every 4-week long-acting injectable cabotegravir and rilpivirine; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: HIV Infections
Interventions: CAB LA+RPV LA; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Sacramento, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more

Conditions: HIV Infections
Interventions: DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 15
States / cities: Birmingham, Alabama • Bakersfield, California • Fort Lauderdale, Florida + 12 more

Conditions: Hiv
Interventions: Collaborative drug therapy management model, Cabotegravir/Rilpivirine; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs